Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mercaptopurine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Mercaptopurine 50 mg |
| 2 | ACTIVE_COMPARATOR | Purinethol® Tablets 50 mg |
| Name | Type | Description |
|---|---|---|
| Mercaptopurine 50 mg | DRUG | 50mg, single dose fasting |
| Purinethol® Tablets 50 mg | DRUG | 50mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male 3. Volunteers are to be sterile (documentation required) or during the course of the study, from study screen until 3 months after study exit, non-sterile male volunteers must use a spermicide-containing barrier method of contraception to...
Mercaptopurine is a small molecule drug candidate developed by Viatris Inc. (ticker: VTRS). It is being studied in Phase 1 clinical development. The specific medical conditions it is intended to treat have not been publicly disclosed, and its therapeutic area is classified as other.
Mercaptopurine targets PPAT, also known as phosphoribosyl pyrophosphate amidotransferase. It acts as an inhibitor of this enzyme. PPAT is involved in purine biosynthesis, and inhibiting it interferes with that pathway. This mechanism defines Mercaptopurine as a small molecule inhibitor directed at PPAT.
Mercaptopurine is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for advancing this small molecule drug candidate through clinical development. The drug is currently in Phase 1 testing.
Mercaptopurine is in Phase 1 clinical development. It is an investigational drug and is not approved. The Phase 1 program includes one completed trial with 60 enrolled participants. No active trials are currently listed for this candidate.
Mercaptopurine has been studied in one completed Phase 1 trial, NCT00648336, titled Fasting Study of Mercaptopurine 50 mg and Purinethol Tablets 50 mg. The trial enrolled 60 healthy male volunteers aged 18 years and older in the United States. It was randomized and active controlled, without double blinding.